(Q46559484)

23 December 2017

http://europepmc.org/abstract/MED/28988646

title

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial (English)

1 reference

23 December 2017

http://europepmc.org/abstract/MED/28988646

main subject

phase II clinical trial

0 references

multicenter clinical trial

1 reference

1 reference

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ruth Salazar

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alexander J. Lazar

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Robert G. Maki

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

6

James Hu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

20

Ignacio I Wistuba

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

7

Sandra D'Angelo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Hussein A Tawbi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Melissa Burgess

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Vanessa Bolejack

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Brian A Van Tine

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Scott M Schuetze

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Steven Attia

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Richard F Riedel

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Dennis A Priebat

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sujana Movva

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lara E Davis

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Scott H Okuno

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

John Crowley

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lisa H Butterfield

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jaime Rodriguez-Canales

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Laurence H Baker

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Denise Reinke

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Shreyaskumar Patel

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

4 October 2017

1 reference

23 December 2017

http://europepmc.org/abstract/MED/28988646

published in

Lancet Oncology Commission

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

1493-1501

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

2 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Programmed cell death ligand 1 expression in osteosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Expression of HLA-A,B,C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Response to anti-PD1 therapy with nivolumab in metastatic sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930624-1

7 January 2021

10.1016/S1470-2045(17)30624-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28988646%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference